STOK
Stoke Therapeutics, Inc. NASDAQ Listed Jun 19, 2019$32.85
Mkt Cap $1.9B
52w Low $8.51
76.8% of range
52w High $40.22
50d MA $34.38
200d MA $28.55
P/E (TTM)
-275.7x
EV/EBITDA
-95.4x
P/B
5.6x
Debt/Equity
0.0x
ROE
-1.9%
P/FCF
41.8x
RSI (14)
—
ATR (14)
—
Beta
1.22
50d MA
$34.38
200d MA
$28.55
Avg Volume
740.0K
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
45 Wiggins Avenue · Bedford, MA 01730 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.80 | -0.79 | +1.2% | 32.79 | -2.7% | +0.3% | — | — | — | — | — |
| Mar 16, 2026 | AMC | -0.75 | -0.97 | -29.3% | 33.96 | -3.2% | -3.2% | -8.7% | -2.3% | -1.3% | -1.6% | — |
| Nov 4, 2025 | AMC | -0.54 | -0.65 | -20.4% | 25.34 | -13.4% | -9.9% | -11.3% | -9.8% | -11.7% | -0.9% | — |
| Aug 12, 2025 | AMC | -0.57 | -0.40 | +29.8% | 13.53 | +10.1% | +25.0% | +26.9% | +34.6% | +36.8% | +36.7% | — |
| May 13, 2025 | AMC | -0.37 | 1.90 | +613.5% | 8.93 | -2.5% | +0.7% | +7.8% | +9.3% | +10.1% | +12.5% | — |
| Mar 18, 2025 | AMC | -0.51 | -0.18 | +64.7% | 8.87 | +0.9% | -6.9% | -6.1% | -8.1% | -6.5% | -12.7% | — |
| Nov 5, 2024 | AMC | -0.52 | -0.47 | +9.6% | 13.05 | +5.0% | +1.5% | +1.7% | +6.4% | +5.8% | +4.4% | — |
| Aug 7, 2024 | AMC | -0.57 | -0.46 | +19.3% | 13.71 | +3.9% | +3.1% | +5.2% | +5.4% | +3.4% | +1.9% | — |
| May 6, 2024 | AMC | -0.60 | -0.57 | +5.0% | 11.87 | +0.1% | +0.6% | -2.3% | +1.2% | -3.3% | -2.7% | — |
| Mar 25, 2024 | AMC | -0.62 | -0.60 | +3.2% | 6.50 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% | — |
| Nov 7, 2023 | AMC | -0.65 | -0.55 | +15.4% | 4.85 | +0.0% | -4.9% | -6.6% | -12.2% | -12.0% | -2.9% | — |
| Aug 7, 2023 | AMC | -0.65 | -0.69 | -6.2% | 5.85 | -2.1% | -5.1% | -4.6% | -2.9% | -7.0% | -6.7% | — |
| May 4, 2023 | AMC | -0.70 | -0.53 | +24.3% | 10.72 | +0.5% | +11.5% | +12.3% | +13.4% | +8.7% | +7.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $33.19 | $34.10 | +2.7% | +1.0% | +0.6% | -3.0% | +1.8% | +1.5% |
| Mar 19 | BTIG | Maintains | Buy → Buy | — | $31.02 | $29.99 | -3.3% | +7.0% | +8.0% | +7.7% | +3.7% | +8.9% |
| Mar 18 | Wedbush | Maintains | Outperform → Outperform | — | $32.87 | $32.85 | -0.1% | -5.6% | +1.0% | +1.9% | +1.6% | -2.1% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $32.87 | $32.85 | -0.1% | -5.6% | +1.0% | +1.9% | +1.6% | -2.1% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $33.96 | $32.89 | -3.2% | -3.2% | -8.7% | -2.3% | -1.3% | -1.6% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $33.96 | $32.89 | -3.2% | -3.2% | -8.7% | -2.3% | -1.3% | -1.6% |
| Jan 12 | Wedbush | Maintains | Outperform → Outperform | — | $32.85 | $27.40 | -16.6% | -10.4% | -6.9% | -5.7% | -10.9% | -12.6% |
| Jan 5 | Chardan Capital | Maintains | Buy → Buy | — | $30.90 | $30.71 | -0.6% | +5.3% | +14.0% | +13.8% | +9.0% | +6.3% |
| Jan 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.90 | $30.71 | -0.6% | +5.3% | +14.0% | +13.8% | +9.0% | +6.3% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.39 | $33.13 | +2.3% | +1.8% | +3.8% | +1.5% | -1.4% | -1.3% |
| Nov 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $25.34 | $21.94 | -13.4% | -9.9% | -11.3% | -9.8% | -11.7% | -0.9% |
| Nov 5 | Wedbush | Maintains | Outperform → Outperform | — | $25.34 | $21.94 | -13.4% | -9.9% | -11.3% | -9.8% | -11.7% | -0.9% |
| Nov 5 | BTIG | Maintains | Buy → Buy | — | $25.34 | $21.94 | -13.4% | -9.9% | -11.3% | -9.8% | -11.7% | -0.9% |
| Nov 3 | JP Morgan | Maintains | Neutral → Neutral | — | $30.04 | $29.30 | -2.5% | -13.1% | -15.6% | -24.0% | -25.2% | -23.9% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $30.19 | $30.18 | -0.0% | +0.5% | +15.7% | +17.9% | +13.2% | +11.1% |
| Oct 10 | Needham | Maintains | Buy → Buy | — | $29.90 | $30.95 | +3.5% | +1.0% | +1.5% | +16.9% | +19.1% | +14.3% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $13.53 | $14.89 | +10.1% | +25.0% | +26.9% | +34.6% | +36.8% | +36.7% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $13.53 | $14.89 | +10.1% | +25.0% | +26.9% | +34.6% | +36.8% | +36.7% |
| Jul 1 | Needham | Maintains | Buy → Buy | — | $11.35 | $11.25 | -0.9% | +2.6% | +1.8% | +1.1% | +3.0% | +5.8% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.93 | $8.71 | -2.5% | +0.7% | +7.8% | +9.3% | +10.1% | +12.5% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $5.90 | $5.76 | -2.4% | +9.0% | +10.5% | +19.0% | +28.1% | +31.4% |
| Mar 19 | Chardan Capital | Maintains | Buy → Buy | — | $8.87 | $8.95 | +0.9% | -6.9% | -6.1% | -8.1% | -6.5% | -12.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.87 | $8.95 | +0.9% | -6.9% | -6.1% | -8.1% | -6.5% | -12.7% |
| Mar 18 | Needham | Maintains | Buy → Buy | — | $9.00 | $8.63 | -4.1% | -1.4% | -8.2% | -7.4% | -9.4% | -7.9% |
| Feb 19 | Chardan Capital | Maintains | Buy → Buy | — | $9.71 | $9.80 | +0.9% | -4.2% | -10.0% | -14.2% | -12.5% | -15.0% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.68 | $10.80 | +1.1% | -9.1% | -12.9% | -18.2% | -22.0% | -20.4% |
| Feb 18 | Needham | Maintains | Buy → Buy | — | $10.68 | $10.80 | +1.1% | -9.1% | -12.9% | -18.2% | -22.0% | -20.4% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $9.31 | $9.54 | +2.5% | -3.8% | -3.3% | -4.2% | -6.8% | +1.9% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.31 | $9.54 | +2.5% | -3.8% | -3.3% | -4.2% | -6.8% | +1.9% |
| Dec 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.76 | $13.89 | +0.9% | -3.6% | -5.7% | -10.5% | -12.4% | -11.0% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $13.05 | $13.70 | +5.0% | +1.5% | +1.7% | +6.4% | +5.8% | +4.4% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.05 | $13.70 | +5.0% | +1.5% | +1.7% | +6.4% | +5.8% | +4.4% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.84 | -0.5% | -7.4% | -13.9% | -9.1% | -7.5% | -5.0% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $13.71 | $14.24 | +3.9% | +3.1% | +5.2% | +5.4% | +3.4% | +1.9% |
| Jul 11 | Wedbush | Maintains | Outperform → Outperform | — | $13.26 | $13.71 | +3.4% | +5.8% | +7.5% | +10.0% | +11.2% | +3.2% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $13.31 | $13.60 | +2.2% | +1.5% | +4.2% | -3.6% | -4.8% | -1.4% |
| May 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.87 | $11.88 | +0.1% | +0.6% | -2.3% | +1.2% | -3.3% | -2.7% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.87 | $11.88 | +0.1% | +0.6% | -2.3% | +1.2% | -3.3% | -2.7% |
| May 6 | Needham | Maintains | Buy → Buy | — | $12.02 | $12.02 | +0.0% | -1.2% | -0.7% | -3.5% | -0.1% | -4.5% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $12.76 | $12.88 | +0.9% | +5.8% | +0.1% | -4.3% | -2.4% | -8.2% |
| Mar 26 | JP Morgan | Maintains | Neutral → Neutral | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Mar 26 | Wedbush | Maintains | Outperform → Outperform | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Mar 26 | TD Cowen | Upgrade | Hold → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +118.0% | +107.7% | +107.5% | +101.2% |
| Feb 16 | Needham | Maintains | Buy → Buy | — | $5.31 | $5.24 | -1.3% | -0.8% | +1.3% | +0.9% | +0.2% | +11.9% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | +12.5% | +7.0% | +5.1% | -1.2% | -0.9% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.85 | $5.73 | -2.1% | -5.1% | -4.6% | -2.9% | -7.0% | -6.7% |
| Aug 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $5.85 | $5.73 | -2.1% | -5.1% | -4.6% | -2.9% | -7.0% | -6.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Sell | 2,243 | $32.79 | $74K | 36,621 | +0.97% | — |
8-K
Unknown — 8-K Filing
Kahn's board appointment under standard compensation terms poses minimal risk, but investors should monitor whether new director expertise meaningfully strengthens governance or strategic oversight capabilities.
Apr 7
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
Stoke's auditor resignation raises red flags about potential accounting disagreements, which could indicate undisclosed financial issues and warrants immediate investor scrutiny of the company's disclosures.
Mar 27
8-K
Stoke Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical SEC schema metadata rather than substantive business information about Stoke Therapeutics.
Mar 3
Data updated apr 27, 2026 3:18am
· Source: massive.com